409 related articles for article (PubMed ID: 25792124)
1. Efficacy and safety of vorapaxar as approved for clinical use in the United States.
Magnani G; Bonaca MP; Braunwald E; Dalby AJ; Fox KA; Murphy SA; Nicolau JC; Oude Ophuis T; Scirica BM; Spinar J; Theroux P; Morrow DA
J Am Heart Assoc; 2015 Mar; 4(3):e001505. PubMed ID: 25792124
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.
Bohula EA; Aylward PE; Bonaca MP; Corbalan RL; Kiss RG; Murphy SA; Scirica BM; White H; Braunwald E; Morrow DA
Circulation; 2015 Nov; 132(20):1871-9. PubMed ID: 26338971
[TBL] [Abstract][Full Text] [Related]
3. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
Bohula EA; Bonaca MP; Braunwald E; Aylward PE; Corbalan R; De Ferrari GM; He P; Lewis BS; Merlini PA; Murphy SA; Sabatine MS; Scirica BM; Morrow DA
Circulation; 2016 Jul; 134(4):304-13. PubMed ID: 27440003
[TBL] [Abstract][Full Text] [Related]
4. Vorapaxar in the secondary prevention of atherothrombotic events.
Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
[TBL] [Abstract][Full Text] [Related]
5. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.
Scirica BM; Bonaca MP; Braunwald E; De Ferrari GM; Isaza D; Lewis BS; Mehrhof F; Merlini PA; Murphy SA; Sabatine MS; Tendera M; Van de Werf F; Wilcox R; Morrow DA;
Lancet; 2012 Oct; 380(9850):1317-24. PubMed ID: 22932716
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
Morrow DA; Alberts MJ; Mohr JP; Ameriso SF; Bonaca MP; Goto S; Hankey GJ; Murphy SA; Scirica BM; Braunwald E;
Stroke; 2013 Mar; 44(3):691-8. PubMed ID: 23396280
[TBL] [Abstract][Full Text] [Related]
7. Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events.
Frampton JE
Drugs; 2015 May; 75(7):797-808. PubMed ID: 25895464
[TBL] [Abstract][Full Text] [Related]
8. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
Bonaca MP; Scirica BM; Creager MA; Olin J; Bounameaux H; Dellborg M; Lamp JM; Murphy SA; Braunwald E; Morrow DA
Circulation; 2013 Apr; 127(14):1522-9, 1529e1-6. PubMed ID: 23501976
[TBL] [Abstract][Full Text] [Related]
9. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.
Cavender MA; Scirica BM; Bonaca MP; Angiolillo DJ; Dalby AJ; Dellborg M; Morais J; Murphy SA; Ophuis TO; Tendera M; Braunwald E; Morrow DA
Circulation; 2015 Mar; 131(12):1047-53. PubMed ID: 25681464
[TBL] [Abstract][Full Text] [Related]
10. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Arif SA; D'Souza J; Gil M; Gim S
Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
[TBL] [Abstract][Full Text] [Related]
11. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).
Bonaca MP; Gutierrez JA; Creager MA; Scirica BM; Olin J; Murphy SA; Braunwald E; Morrow DA
Circulation; 2016 Mar; 133(10):997-1005. PubMed ID: 26826179
[TBL] [Abstract][Full Text] [Related]
12. Vorapaxar in the secondary prevention of atherothrombosis.
Tantry US; Liu F; Chen G; Gurbel PA
Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
[TBL] [Abstract][Full Text] [Related]
13. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial.
Bonaca MP; Scirica BM; Braunwald E; Wiviott SD; Goto S; Nilsen DW; Bonarjee V; Murphy SA; Morrow DA
J Am Coll Cardiol; 2014 Dec; 64(22):2318-26. PubMed ID: 25465417
[TBL] [Abstract][Full Text] [Related]
14. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial.
Qamar A; Morrow DA; Creager MA; Scirica BM; Olin JW; Beckman JA; Murphy SA; Bonaca MP
Vasc Med; 2020 Apr; 25(2):124-132. PubMed ID: 32000630
[TBL] [Abstract][Full Text] [Related]
15. Vorapaxar in atherosclerotic disease management.
Cheng JW; Colucci V; Howard PA; Nappi JM; Spinler SA
Ann Pharmacother; 2015 May; 49(5):599-606. PubMed ID: 25680760
[TBL] [Abstract][Full Text] [Related]
16. Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.
Lam S; Tran T
Cardiol Rev; 2015; 23(5):261-7. PubMed ID: 25923910
[TBL] [Abstract][Full Text] [Related]
17. Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial.
Bonaca MP; Creager MA; Olin J; Scirica BM; Gilchrist IC; Murphy SA; Goodrich EL; Braunwald E; Morrow DA
JACC Cardiovasc Interv; 2016 Oct; 9(20):2157-2164. PubMed ID: 27765312
[TBL] [Abstract][Full Text] [Related]
18. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
Tricoci P; Huang Z; Held C; Moliterno DJ; Armstrong PW; Van de Werf F; White HD; Aylward PE; Wallentin L; Chen E; Lokhnygina Y; Pei J; Leonardi S; Rorick TL; Kilian AM; Jennings LH; Ambrosio G; Bode C; Cequier A; Cornel JH; Diaz R; Erkan A; Huber K; Hudson MP; Jiang L; Jukema JW; Lewis BS; Lincoff AM; Montalescot G; Nicolau JC; Ogawa H; Pfisterer M; Prieto JC; Ruzyllo W; Sinnaeve PR; Storey RF; Valgimigli M; Whellan DJ; Widimsky P; Strony J; Harrington RA; Mahaffey KW;
N Engl J Med; 2012 Jan; 366(1):20-33. PubMed ID: 22077816
[TBL] [Abstract][Full Text] [Related]
19. Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50.
Kidd SK; Bonaca MP; Braunwald E; De Ferrari GM; Lewis BS; Merlini PA; Murphy SA; Scirica BM; White HD; Morrow DA
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27431644
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.
Correa S; Bonaca MP; Scirica BM; Murphy SA; Goodrich EL; Morrow DA; O'Donoghue ML
J Thromb Thrombolysis; 2019 Apr; 47(3):353-360. PubMed ID: 30511258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
